Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
The discovery of metabotropic glutamate receptors in the early '90s opened up a new world of potential drug targets in CNS diseases and beyond. But targeting specific mGluRs proved difficult; eventually the challenge of designing selective molecules led to breakthroughs modulating receptors at sites distinct from the endogenous binding site. This so-called allosteric modulation may help to clear a logjam of undruggable GPCRs and other receptors. Creating drug-like molecules remains a challenge but industry, after some false starts, is poised to make advances as compounds begin to hit proof-of-concept in man.
You may also be interested in...
Tiny Seaside Therapeutics is doing pioneering work to develop disease-modifying drugs for Autism Spectrum Disorders, a group of syndromes that not long ago was thought immutable and even blamed on bad parenting. By targeting molecular pathways associated with the single gene disorder fragile X syndrome, Seaside hopes to extrapolate its work to other “autisms” and help people most affected by those disorders learn to walk, talk, or even live independent lives.
With one Phase III trial failed and a second halted for futility, Eli Lilly calls it quits on pomaglumetad methionil, a compound the pharma had hoped would succeed blockbuster antipsychotic Zyprexa, marking the end of the road for a pioneering compound in the effort to drug metabotropic glutamate receptors (mGluRs), a promising class for CNS therapies.
With 15 programs in various stages of early development, the Swiss biotech ratchets up the emphasis on partnering to gain back support and non-dilutive capital after the failure of its lead compound.